Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would love some of what you are smoking, my guy has some great shit but yours's seems to be phenomenal
Shorts have done good pushing her hard, helps with cost basis, hope they hold it here under 3 for the day at least, starting to fill sacks.
No brainer this one.
Peace out
NO I meant short term $2 sorry 4-5 mid term.
The offering was direct not on the open market @1.6825 per share so one can assume that paying 1.35-1.40 range is golden IMO.
Peace out.
Accumulating 1.40's here going back to 12 at least direct offering to institutional buyer was 1.6825 I am .2825 ahead of the game in my book.
Peace out.
$CDR Namco Realty, LLC has filed Form SC 13G with SEC. Reporting 8.8% Ownership.
https://stocknewsflow.com/761648_000106299320002675_0001062993-20-002675
$CDR has collected 73% of base rents and monthly charges for April, and 72% for May, as of the end of last month.
https://seekingalpha.com/news/3579537-cedar-realty-updates-on-april-may-rent-collections?utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated
No brainer within a Q dividend back to .05-.06 by fall back to normal .12 per Q .48 per share per year, selling for under a buck? I am your Huckleberry.
Peace out.
Nice, things moving along well, will get to see more of an uptick in price/revenues/earnings this coming Q but the real separator will be the next one with 2 full Q's no covid and a full quarter of revs from acquisition and product launch.
Looking forward to see the revs from partial covid Q as well, the acquisition gives them what $22-23 million a quarter of positive cash flow and EPS?
Looking forward to XMAS, wish those cheap covid shares were still available.
Peace out.
This one a complete no brainer, last ER $6 covid dropped it but had no effect on business had a bang up Q ER/CC AH's Monday doesn't take a rocket scientist to see how it is moving forward without missing a beat.
Perceptron Announces AccuSite® Order Expansion
Company Release - 4/30/2020
http://investors.perceptron.com/File/Index?keyFile=403817190
Perceptron Announces North American Order for Multi-Robot AccuSite®
Company Release - 1/23/2020
http://investors.perceptron.com/File/Index?keyFile=402413422
Perceptron Announces Order for AccuSite® in Robot Guidance Application
Company Release - 1/9/2020
http://investors.perceptron.com/File/Index?keyFile=402184066
Perceptron Announces First Order for Multi-Robot AccuSite®
Company Release - 12/19/2019
http://investors.perceptron.com/File/Index?keyFile=401751471
Perceptron Announces Global Alliance with Coherix for Bead Inspection
Partnership to leverage strengths of two leading vision manufacturers
Company Release - 11/21/2019
http://investors.perceptron.com/File/Index?keyFile=401163399
Peace out.
Started accumulating in earnest today, going back 3+ will hit 5-6 by fall. Leader in its game, nuff said.
Peace out.
$MNLO They have an approval, with $50 mil in cash, a 50+ person sales force with 6K+ clients, a manufacturer in place ready to roll, nice.
FX-105 phase two results due soon.
Upgrades are coming...................................
Peace out
Menlo Therapeutics Announces Covered Status for AMZEEQ® (minocycline) topical foam, 4%, on Additional Commercial Formulary May 27, 2020 08:00 ET
Coverage Effective Immediately on One of the Largest Payor Networks in the U.S.
AMZEEQ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne
BRIDGEWATER, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its novel AMZEEQ® (minocycline) topical foam, 4%, for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older, has been added to the prescription drug formulary of one of the largest payors in the U.S. AMZEEQ was approved by the U.S. Food and Drug Administration in October 2019.
“We are pleased with the continued expansion of our national coverage for AMZEEQ. With this additional plan under contract, we now have coverage for up to 60% of the total commercial lives in the United States,” said David Domzalski, Chief Executive Officer of Menlo. “This is great news as it allows for AMZEEQ to be more broadly accessible to millions of moderate to severe acne patients.”
Minocycline, a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, has not previously been available as a topical treatment due to its instability in traditional topical formulations. In AMZEEQ, Foamix has leveraged its proprietary Molecule Stabilizing Technology (MST™) platform to deliver minocycline in a foam-based vehicle that maintains the stability of the active ingredient while delivering it directly on the skin.
River of catalysts coming.
Ta Ta kids.
Beautiful chart, all coming together perfectly. Never had any doubt.
Peace out.
Interesting turn of events, make one wonder, just what is going on out there, who is buzzing around, etc. If it were the 80's this would have been swallowed up at least controlling interest and it would have been broken up a while ago.
Too much value with LB and Ann Inc. iconic names and debt is nothing in the big scheme of things they played it perfectly. First paying their loan payments 18 months ahead a year ago, then buying discounted debt every chance they got.
I like how things are unfolding, you don't protect something that is worthless, nuff said shorty kins.
Peace out.
I will just go on being right, the rest of you can carry on. River of catalysts starting June 2nd.
Ta Ta
Peace out.
Cedar Realty Trust (NYSE:CDR) Rating Increased to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Cedar Realty Trust (NYSE:CDR) from a hold rating to a buy rating in a research report released on Monday, Zacks.com reports. They currently have $0.75 price target on the real estate investment trust’s stock.
According to Zacks, “Cedar Realty Trust, Inc. is a real estate investment trust which owns a portfolio of predominantly grocery-anchored shopping centers in high-density urban markets from D.C. to Boston. Cedar Realty Trust Inc, formerly known as Cedar Shopn Ctr, is based in Port Washington, NY. “
Several other equities research analysts have also recently commented on the company. ValuEngine upgraded Cedar Realty Trust from a strong sell rating to a sell rating in a research note on Thursday, April 30th. TheStreet cut Cedar Realty Trust from a c- rating to a d+ rating in a research note on Friday, February 7th. Finally, B. Riley cut their price target on Cedar Realty Trust from $5.00 to $2.00 and set a buy rating for the company in a research note on Friday, April 3rd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $1.58.
A number of large investors have recently added to or reduced their stakes in CDR. SG Americas Securities LLC raised its position in Cedar Realty Trust by 61.6% in the first quarter. SG Americas Securities LLC now owns 34,008 shares of the real estate investment trust’s stock worth $32,000 after acquiring an additional 12,965 shares in the last quarter. Cresset Asset Management LLC purchased a new position in Cedar Realty Trust in the fourth quarter worth $33,000. Raymond James & Associates purchased a new position in Cedar Realty Trust in the fourth quarter worth $36,000. Premier Asset Management LLC purchased a new position in Cedar Realty Trust in the first quarter worth $45,000. Finally, Nisa Investment Advisors LLC raised its position in Cedar Realty Trust by 36.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 15,475 shares of the real estate investment trust’s stock worth $46,000 after acquiring an additional 4,143 shares in the last quarter. Hedge funds and other institutional investors own 87.04% of the company’s stock.
Yeah I think this one is going for a ride we shall see.
What Makes Ocugen (OCGN) a New Strong Buy Stock
Zacks Equity Research
May 21, 2020
Ocugen (OCGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Ocugen is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
For Ocugen, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.
Earnings Estimate Revisions for Ocugen
This biotech knee implant developer is expected to earn -$0.15 per share for the fiscal year ending December 2020, which represents a year-over-year change of 89.9%.
Analysts have been steadily raising their estimates for Ocugen. Over the past three months, the Zacks Consensus Estimate for the company has increased 58.3%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Ocugen to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Wow, ghost town here. Virtual shareholder deal next week, liking how they are going tome out of flu deal, Q1 much better than anyone anticipated IMO.
We shall see. What's not to like 52 week bottom test today all signs point north. Looking for it to return back to its 2.50-3.00 channel leg it up from here, building as it goes.
Peace out.
Yeah, that 10Q pretty much sums it up, haven't a clue what is going on there, but, common sense tells me it isn't good.
Have to close the book on this one and move on, I wouldn't buy back in for.05 a share.
Peace out.
Who cares what Piper Sandler said about Menlo? I will se you fools in December.
Others, use the hustle these people play to your benefit, play the channel they provide to flip 25% of your position to build size to your position, leaving the other 75% at GTC orders $5+
The game is already won, its just a case of finding out the final score.
Peace out.
Use the small money nitwits to your advantage. I do it every day, day in and day out.
Well are you guys serious? No one really gives a damn I have made dozens of people more than 1/2 million on single stock, many on this site. I made over 2 Mil on this bitch. I will be glad when the herd moves on to the next watering hole.
But that _hit doesn't mean a hill of beans, seriously people.
Now back to what the boards are for.
rickn23 I owe you an apology as I sit with egg on my face, I had taken a nap even before the market closed and just now saw the late filing and had to do a triple take at the revs for Q1.
Am dying to see just how that broke down, if RR season 2 that debuted in October was not paid for in Q4 2019 and not this past Q1 just when the hell did that $$ come in? I want to know when things are counted etc, one thing when doing the run through of revs per Q in each category there were two that were much higher in Q2 as opposed to other Q's, not into digging for it now, will this weekend as I try and understand, if one can the # they threw out there, $400K and without $$ for RR for one besides other things.
I would love to get, and want a break down of their revenue streams etc when/what etc. From today not 2015 etc. And CCTV in China if RR season 1 to ick Jr Latin America was $300K or whatever then CCTV should be at least that and that was February, trial run Jan inked deal in Feb?
I am go back through Q's but I am almost positive that RR season 2 shows up nowhere (the cash) so I am wondering just what happened to that, CCTV and I want to get a cleared picture as to when/what this revenue stream and that revenue stream comes in, that's the next thing I want to see from Heyward.
This is like throwing darts trying to figure out, bullshit it is.
But yes, humblest apologies ricnk23 and whatever the other cats name is you were right and I was most certainly wrong.
Peace out
NP, glad to pay forward the advice I was taught way back in the early Raging Bull days by some retired old school players from when the "street" was still the "street"
Peace out
You were right to do so, and its why I just posted once and wanted all the people that follow me as real investors to be aware. It is still an awesome investment and will be $1+ by August and multiple $'s 12 months out, but, now, no. Is doing all the right things, revs/EPS are going going to start rising meaningfully, but, not to the extent that today it can sustain a share price like that. Come August with all the new Skus another RR season more growth as the popularity grows the new lines come out in June July August and there are another 2-3 LL books based on the series the other 2 RR books come out another 2 DVD's a piece, sell to a few more countries/territories we haven't yet for RR, get a new season of Llama Llama ordered, be 5-6 months from the worldwide debut of SK etc. yes, but now, take it when you can get it and then summer time when the market is what it is, snipe the shit out of it and build back up for August forward when it will be a solid $1+ and stay there.
Peace out.
Anyone who is retail in this and follows me, you better take profits this is way to far way to fast this is a momo thing and has zero to do with reality, get your money.
I good, but, still. Good none the less.
That is okay, but, I am still awaiting HC Wainwright analyst Ram Selvaraju who actually covered Foamix and had a PT of $11 weigh in.
Analysts know companies and everything about that company and the other 30 they cover in a sector for a firm like Wainright.
H.C. Wainwright analyst Oscar (Oren) Livant who covered Menlo and lowered the target he had for Menlo and Seroplant from $8 to $2 now ups it to $2.50 maintaining his buy rating after the ER is valuing it on cash alone, nothing else as he hasn't a clue about Foamix nor should he.
Doesn't bum me out, but I am still awaiting the Foamix analysts to give their .02 cents. And, they are coming soon, whether before or after approval I haven't a clue but when the Foamix analyst speak that's when this flips a switch and gets normal.
Peace out.
They cannot RS
There goes the neighborhood.
Menlo changed, its no more, the CEO s there they game him a directors seat. All that is left is the structure, the HQ and the cash they left, no pipeline no former employees etc. Foamix RMed into it Menlo was a cash burning waste, sorry to be harsh but it is what it is.
if Foamix didn't RM into it, they would have wasted the last of their $$ trying for what the 6th time to find something that Seroplant was good for, but, luckily large shareholders said, no. Your cash burning days are over.
This is Foamix in all but ticker symbol and name and nothing of Menlo except those two things.
Peace out.
Never doubted it for a second. nice.
Peace out.
Okay, people not taking things serious, I will just go back to not checking the page again, The general public, wow.
Just a question with the CCTV sale for RR seasons to China Q1 the Viacom payment for Season 2 which had yet to be paid in Q4.
With 80+ skus of "real" merchandise begin sold as compared to last year why is it you would think that they would do either $250K less that last year or $500K more than last year.
I really would like to understand your reasoning, for 4 straight Q's they increased YoY revenues in each category but this one they are going step back some 75-80% and instead lose in every category I find it fascinating actually just seeing how peoples minds work.
Because $1 million is 200+K less than last year, just give me a heads up how you got there?
ThanKs.
Throw up your guesses for what you think the revenue number will be. Don't throw some stupid shit out there, Q1 is big pay Q for them from multiple sources including majority of Q4 royalty payments for holiday sales. Maybe can get an honest discussion amongst longs here.
From last years, a guide as it were to make serious estimate.
Television & Home Entertainment revenue is generated from distribution of our properties for broadcast on television, VOD, or SVOD in domestic and international markets and the sale of DVDs for home entertainment through our partners
Licensing and royalty revenue include items for which we license the rights to our copyrights and trademarks of our brands and those of the brands for which we act as a licensing agent.
Also included will be:
Payment for receipt of Rainbow Rangers season 2 from Viacom
The CCTV (China) payment for Rainbow Rangers season one
Last years $$
Television & Home Entertainment $850,107
Licensing & Royalties $350,186
Take a minute weight DVD's they had 2018 one I think, all the added books and the large difference in merchandised goods which is 100%'s higher than what they had in 2018 Q4 when they had almost none except Llama Llama stuffed animals and Baby Genius toys.
See if we can get some decent discussion, opinions.
I am $3.5 to $4 million for the Q as opposed to $1.22 million for last years Q1
Peace out.
Noticed in a Facebook page today there was a pen that is one of the items that is in the roll out of the Inkology stationary line.
https://www.facebook.com/RainbowRangersOfficial/photos/a.1964861440218269/2970697942967942/?type=3&theater
This one too from 2 weeks ago had two of them.
https://www.facebook.com/RainbowRangersOfficial/photos/a.1964861440218269/2938184852885918/?type=3&theater
https://online.fliphtml5.com/guep/ttwz/#p=2
I am not 100% sure when that line was rolled out last year it was some time in May at Office Depot and June 1st the notebooks/folders appeared on Amazon. But they also supply many other retailers when it comes to pens etc. impulse stuff on counters at Michaels etc. type stores. Maybe they are one of the things Walmart is going to stock which Heyward was referring to, haven't a clue.
Next Llama Llama book on series is out in a couple weeks and they said they would continue to have DVD's roll out on a consistent basis I am guessing will be like Llama Llama was last year and RR has had since Dec 4th? One is certainly due its 3 months to the day since the last two on February 2nd. One per Q glad the shirts for RR are back, they had sold out, the trio sets sold out in various sizes multiple times, would like to see those in larger sizes not just toddlers, maybe they will.
The next two RR books they said will be out in late July with the merchandise drop that coincides with Season 3 of RR, was surprised there was no "official" PR that they got picked up for one, I think there is so much going on now, that they are just going to have shareholder letters start coming on a more regular basis and CC's will be more of a way to update such things.
Fine with me, we all know it rocking now and I look forward to the next 6-12 months indeed.
Peace out.
Girls they have the most unusual things to have an issue with, reviews are nice, though one young lady thinks yellow was a bad color, "like, really. Who wold make it that color"? LOL
https://www.webmd.com/drugs/drugreview-178351-amzeeq-foam.aspx?drugid=178351&drugname=amzeeq-foam
I never posted this here, but did on the other biotech when it was being toyed with by short selling groups that like to hit it all at once. I you are long and have a position put your shares up for sale 10+ in sperate lots, it does help, it take the shares they are allowed to borrow down and increases the cost for shares they can.
Peace out.
Never posted this here, but did on the other biotech when it was being toyed with by short selling groups that like to hit it all at once. I you are long and have a position put your shares up for sale 10+ in sperate lots, it does help, it take the shares they are allowed to borrow down and increases the cost for shares they can.
Peace out.
Not sure how many keep up with the actual written papers/publications of acne etc. For those who are longs here are the two latest on acne and its treatment. The first is on preferred methods of acne treatment unless someone has extremely serious acne from March 25th 2020 the second is one on the newest treatment options a week later April 2nd.
Amzeeq is a retinoid and a tetracycline antibiotic based topical treatment and hold the patent until 2030.
https://www.dermatologytimes.com/acne/expert-offer-insight-isotretinoin-use
https://www.dermatologytimes.com/acne/treatment-options-acne-expand
FWIW it is always good to keep up with what the industry/doctors etc are talking about, and their views on preferred treatments when invested in a company with product, goes without saying but many never think to keep up with it, in most cases IMHO it gives better insight into any treatment/medication they are the ones that will be seeing patients.
Peace out.
No problem, that has been the confusion with MNLO since the merger etc. they had only been merged a short time and the perfect example is the two separate analysts covering MNLO from HC Wainwrights two sperate analysts.
H.C. Wainwright analyst Oscar Livant covered/researched etc. the one MNLO had PT $8 when MNLO failed the two trials he went to $2 because although they had no pipeline and Seroplant was now thrown in the bin he dropped to $2 because they had a shit ton of cash. He knew/knows nothing about FOMX that wasn't in his wheelhouse he can't give an opinion on it, so he went with what he had and knew, shit ton of cash and nothing else.
HC Wainwright analyst Ram Selvaraju for FOMX had it at 10-11 never $8 it has never in its history had a price target below $10.
Its apples and oranges, it is getting sorted though 2 of the 3 firms I buy reports on FOMX are going to be releasing new reports, then bye bye birdie. You had FOMX insane pipeline products, partners PDUFA June 2 recent commercial launch nationwide sales force in place manufacture sales for already set for quick launch after June 2 PDUFA Amzeeq partnership/licensing deal with $11 mil cash up front for the right to sell Amzeeq on the most populated market in the world and with expansion of that partnership with FMX-103 on the horizon.
It doesn't a rocket scientist to figure it out, but, I will be glad when the two reports hit, it will start to help clarify all the confusion. As I said before looking up info for MNLO you may as well look up info for Jonny's watermelon patch there is absolutely no real info in doing so.
Like I said my first post I only post for real investors on Ihub so they can understand realities as 99% of the posters on Ihub post headlines because they know nothing else, they just trade Letters.
Shorts hit it hard yesterday 58% short volume to many big blocks being loaded though, the street is buying IMHO after the Chinese/Taiwan/Macau deal and they too without a doubt no what I di that clarifications are coming from analysts for FOMX at least two haven't a clue about the other 3.
Peace out all.
Exactly, the only thing left is two board members from Menlo and the cash, nothing else and the down grades their company got was they were being priced @2 because they had all that cash, but had no products, deals, revenues, PDFUF ahead etc etc etc.
If one was to ever get into a biotech at the right time, and certainly and insanely right price its this one as was the other we were in when it was pushed to 1-2
You do not find them at this stage of the game facing the $$$ they are facing and having a market cap based just on their cash alone, that is like???????????
The numbers and info you can find on this company now which are based solely on Menlo Thera hell you may as well shake a cup of Yatzee dice and toss them and use those numbers, they bare no resemblance to reality. PT average $6.80 its never had a PT lower than $10 singularly let alone an average one.
Peace out.